Since it was first approved by the FDA in 2017, Dupixent® (dupilumab) has been prescribed to thousands of Americans. Unfortunately, recent studies have found evidence that Dupixent may be linked to cutaneous T-cell lymphoma (CTCL).
If you have been prescribed Dupixent and were diagnosed with cutaneous T-cell lymphoma, you may be entitled to compensation from its manufacturer.
What is Dupixent?
Sanofi and Regeneron Pharmaceuticals, Inc. manufacture Dupixent, a prescription medication that treats a range of inflammatory conditions, such as:
- Uncontrolled moderate to severe eczema (atopic dermatitis or AD)
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic urticaria not controlled by H1 antihistamines
- Bullous pemphigoid
As well as an add-on treatment for:
- Chronic obstructive pulmonary disease (COPD)
- Certain types of asthma
- Uncontrolled chronic rhinosinusitis with nasal polyps
Dupxient works by blocking the signaling of two key sources of inflammation that play a key role in the development of conditions like asthma, eczema, COPD, rhinosinusitis, and others.
The drug’s packaging lists possible side effects, including allergic reactions, eye problems, and injection site reactions, among others. However, many users have also reported serious blood and lymphatic system disorders, including cancer.
What is cutaneous T-cell lymphoma?
Cutaneous T-cell lymphoma (CTCL) is a type of cancer that starts in T-cells, a kind of white blood cell that helps the immune system fight germs, bacteria, and other foreign substances. In CTCL, these T-cells mistakenly attack the skin.
T-cell lymphomas can also develop in other lymphoid tissues such as the lymph nodes, gastrointestinal tract, and spleen.
Because the disease can affect different areas of the body, symptoms may vary depending on where it begins. Symptoms may include:
- Heavy night sweats
- Pain in the stomach, bones, or chest
- Chronic fatigue
- Hair loss
- Swollen lymph nodes
- Unexplained weight loss
- Red, scaly patches on the skin that may be flaky or itchy
- Thickened skin on the palms of the hands and feet
Can Dupixent cause cutaneous T-cell lymphoma?
Several medical reports and studies suggest that Dupixent may increase the risk of CTCL.
One study published (Hasan, et al.) in April 2024 examined whether people with atopic dermatitis treated with Dupixent had a higher risk of developing CTCL than those who did not take the drug. After adjusting for factors such as age, sex, race, and ethnicity, and excluding participants who had taken certain other immunosuppressive drugs, they found users were more than twice as likely to develop CTCL.
A second study (Mandel, et al.) used a similar approach to the April 2024 study. Researchers excluded patients with other inflammatory conditions or those who had taken biologic drugs potentially linked to lymphoma. After adjusting for other factors, the researchers found that Dupixent-treated people with atopic dermatitis were more than four times as likely to develop CTCL as those not treated with the drug.
In June 2025, another study (Sheng-Kai, et al.) investigated the risk of blood cancers in asthma patients who started Dupixent compared with those using a common inhaled treatment. They found that the risk of CTCL was more than 4.5 times higher in the Dupixent group.
Researchers also linked Dupixent to an overall increased risk of all types of lymphoma. Among patients who had taken their medications for at least 16 weeks, the risks rose further.
What is the Dupixent lawsuit?
Lawsuits against Dupixent began emerging in late 2024 and into 2025, following the publication of the studies mentioned above, which showed an increased risk of CTCL among patients who used the drug.
According to the FDA Adverse Event Reporting System (FAERS) 1,820 reports of blood and lymphatic system disorders, 132,359 reports of skin and subcutaneous tissue disorders, and 1,300 deaths have been submitted in connection with Dupixent to the FDA. These numbers include cases of CTCL.
These claims and reports have reached the FDA, which, as of March 2025, is evaluating whether regulatory action is needed and has begun investigating potential safety concerns.
These findings have prompted lawsuits alleging that the manufacturer failed to warn patients about these risks adequately.
Joining the Dupixent lawsuit
You may qualify for the Dupixent lawsuit against Dupixent manufacturers Sanofi and Regeneron Pharmaceuticals, Inc. if you or a loved one:
- Used Dupixent as prescribed
- Were later diagnosed with T-cell lymphoma, especially cutaneous T-cell lymphoma
- Are within your state’s statute of limitations
If you or a loved one developed cutaneous T-cell lymphoma, other serious side effects, or worsening symptoms after taking Dupixent, you may have a case.
"*" indicates required fields
Dupixent® is a registered trademark of Sanofi and Regeneron Pharmaceuticals, Inc. Their names are used here only for the purpose of identifying the products in question. Woods & Woods, LLC is not affiliated with, sponsored by, or associated with the FDA, Sanofi, Regeneron Pharmaceuticals, Inc., Cleveland Health Clinic, Mayo Clinic, Wiley Online Library, or the National Library of Medicine. Never stop taking a medication without first talking to your doctor.
